FDA panel backs new diabetes drug

Share this article:
An FDA advisory panel on Friday endorsed Bristol-Myers Squibb's and Merck's Pargluva, developed to control blood sugar levels and cholesterol in people with Type-2 diabetes.
Members of the FDA's Endocrinologic and Metabolic Drugs advisory committee voted 8-1 to recommend approval of Pargluva to treat Type 2 diabetes alone. The panel voted 7-2 to endorse its use alongside another treatment, metformin.
However, the panel also voted 6-3 against recommending Pargluva's use in combination with sulfonylurea, another drug that prompts the pancreas to release more natural insulin into the bloodstream.
Although it is not required to do so, the FDA usually follows the advice of its advisory panels.
Share this article:

Email Newsletters

More in Business Briefs

Massachusetts painkiller ban overruled

A District Court says Massachusetts cannot ban opioid painkiller Zohydro.

Ranbaxy extends branded Diovan's life

Ranbaxy may be on the blocks, but it has a hold on the right to produce generics of the Novartis heart medication Diovan. Only problem: it can't, and that is good news for Novartis.

FDA approves Glaxo's GLP-1

Type-2 diabetes injection Tanzeum, also known as albiglutide, scored the approval Tuesday.